Jazz Pharmaceuticals PLC (JAZZ) saw its stock price surge 5.28% in pre-market trading on Wednesday.
The sharp rise follows a series of positive analyst actions, with at least three major financial institutions raising their price targets for the company. Bofa Global Research increased its price objective to $275 from $263, Wells Fargo lifted its target to $250 from $235 while maintaining an Overweight rating, and Morgan Stanley raised its target to $226.00 from $225.00.
These upward revisions reflect growing analyst optimism about Jazz Pharmaceuticals' prospects in the healthcare sector, prompting increased investor interest before the market open.
Comments